University of Calgary Tom Baker Cancer Center, Calgary, Alberta, Canada.
Ottawa Hospital Centre for Transfusion Research, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
J Clin Oncol. 2020 May 1;38(13):1463-1473. doi: 10.1200/JCO.19.01836. Epub 2020 Feb 21.
Evidence regarding red blood cell (RBC) transfusion practices and their impact on hematopoietic cell transplantation (HCT) outcomes are poorly understood.
We performed a noninferiority randomized controlled trial in four different centers that evaluated patients with hematologic malignancies requiring HCT who were randomly assigned to either a restrictive (hemoglobin [Hb] threshold < 70 g/L) or liberal (Hb threshold < 90 g/L) RBC transfusion strategy between day 0 and day 100. The noninferiority margin corresponds to a 12% absolute difference between groups in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score relative to baseline. The primary outcome was health-related quality of life (HRQOL) measured by FACT-BMT score at day 100. Additional end points were collected: HRQOL by FACT-BMT score at baseline and at days 7, 14, 28, 60, and 100; transplantation-related mortality; length of hospital stay; intensive care unit admissions; acute graft-versus-host disease; Bearman toxicity score; sinusoidal obstruction syndrome; serious infections; WHO Bleeding Scale; transfusion requirements; and reactions to therapy.
A total of 300 patients were randomly assigned to either restrictive-strategy or liberal-strategy treatment groups between 2011 and 2016 at four Canadian adult HCT centers. After HCT, mean pre-transfusion Hb levels were 70.9 g/L in the restrictive-strategy group and 84.6 g/L in the liberal-strategy group ( < .0001). The number of RBC units transfused was lower in the restrictive-strategy group than in the liberal-strategy group (mean, 2.73 units [standard deviation, 4.81 units] 5.02 units [standard deviation, 6.13 units]; = .0004). After adjusting for transfusion type and baseline FACT-BMT score, the restrictive-strategy group had a higher FACT-BMT score at day 100 (difference of 1.6 points; 95% CI, -2.5 to 5.6 points), which was noninferior compared with that of the liberal-strategy group. There were no significant differences in clinical outcomes between the transfusion strategies.
In patients undergoing HCT, the use of a restrictive RBC transfusion strategy threshold of 70 g/L was as effective as a threshold of 90 g/L and resulted in similar HRQOL and HCT outcomes with fewer transfusions.
有关红细胞(RBC)输血实践及其对造血细胞移植(HCT)结果影响的证据了解甚少。
我们在四个不同的中心进行了一项非劣效性随机对照试验,评估了需要 HCT 的血液系统恶性肿瘤患者,这些患者在第 0 天至第 100 天期间随机分配至限制性(血红蛋白[Hb]阈值<70 g/L)或宽松性(Hb 阈值<90 g/L)RBC 输血策略。非劣效性边界对应于基线时功能性评估癌症治疗-骨髓移植(FACT-BMT)评分相对于基线的两组之间 12%的绝对差异。主要结局是第 100 天时通过 FACT-BMT 评分测量的健康相关生活质量(HRQOL)。收集了其他终点:基线时和第 7、14、28、60 和 100 天时通过 FACT-BMT 评分测量的 HRQOL;移植相关死亡率;住院时间;重症监护病房入院;急性移植物抗宿主病;Bearman 毒性评分;窦状隙阻塞综合征;严重感染;世界卫生组织出血量表;输血需求;以及对治疗的反应。
2011 年至 2016 年期间,在加拿大四个成人 HCT 中心,共有 300 名患者随机分配至限制性策略或宽松性策略治疗组。HCT 后,限制性策略组的平均预输血 Hb 水平为 70.9 g/L,宽松性策略组为 84.6 g/L(<0.0001)。限制性策略组输注的 RBC 单位数低于宽松性策略组(平均,2.73 单位[标准差,4.81 单位] 5.02 单位[标准差,6.13 单位];=0.0004)。在调整输血类型和基线 FACT-BMT 评分后,限制性策略组第 100 天的 FACT-BMT 评分更高(差值 1.6 分;95%CI,-2.5 至 5.6 分),与宽松性策略组相当。两种输血策略之间在临床结局方面无显著差异。
在接受 HCT 的患者中,使用 70 g/L 的限制性 RBC 输血策略阈值与使用 90 g/L 的阈值一样有效,且可导致相似的 HRQOL 和 HCT 结局,同时输血更少。